200 related articles for article (PubMed ID: 28601493)
21. Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma.
Jones CI; Zabolotskaya MV; King AJ; Stewart HJ; Horne GA; Chevassut TJ; Newbury SF
Br J Cancer; 2012 Dec; 107(12):1987-96. PubMed ID: 23169280
[TBL] [Abstract][Full Text] [Related]
22. Circulating microRNA expression is associated with genetic subtype and survival of multiple myeloma.
Huang JJ; Yu J; Li JY; Liu YT; Zhong RQ
Med Oncol; 2012 Dec; 29(4):2402-8. PubMed ID: 22447484
[TBL] [Abstract][Full Text] [Related]
23. Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma.
Yue X; Lan F; Hu M; Pan Q; Wang Q; Wang J
J Neurosurg; 2016 Jan; 124(1):122-8. PubMed ID: 26230475
[TBL] [Abstract][Full Text] [Related]
24. Elevated Th22 as well as Th17 cells associated with therapeutic outcome and clinical stage are potential targets in patients with multiple myeloma.
Wang M; Chen P; Jia Y; He N; Li D; Ji C; Ma D
Oncotarget; 2015 Jul; 6(20):17958-67. PubMed ID: 26255628
[TBL] [Abstract][Full Text] [Related]
25. The diagnostic and prognostic values of circulating miRNA-1246 in multiple myeloma.
Zhao G; Jing X; Li Z; Wu X; Gao Z; Ma R
Hematology; 2022 Dec; 27(1):778-784. PubMed ID: 35793786
[TBL] [Abstract][Full Text] [Related]
26. Clinical relevance of circulating cell-free microRNAs in ovarian cancer.
Nakamura K; Sawada K; Yoshimura A; Kinose Y; Nakatsuka E; Kimura T
Mol Cancer; 2016 Jun; 15(1):48. PubMed ID: 27343009
[TBL] [Abstract][Full Text] [Related]
27. Circulating miRNA-122, miRNA-199a, and miRNA-16 as Biomarkers for Early Detection of Hepatocellular Carcinoma in Egyptian Patients with Chronic Hepatitis C Virus Infection.
El-Abd NE; Fawzy NA; El-Sheikh SM; Soliman ME
Mol Diagn Ther; 2015 Aug; 19(4):213-20. PubMed ID: 26133725
[TBL] [Abstract][Full Text] [Related]
28. Aberrant microRNA expression in multiple myeloma.
Dimopoulos K; Gimsing P; Grønbæk K
Eur J Haematol; 2013 Aug; 91(2):95-105. PubMed ID: 23586898
[TBL] [Abstract][Full Text] [Related]
29. The role of cystatin C in multiple myeloma.
Zhang J; Jiang Y; Guo D; Liu HY; Hong L; Qi J; Huang H
Int J Lab Hematol; 2022 Feb; 44(1):135-141. PubMed ID: 34549533
[TBL] [Abstract][Full Text] [Related]
30. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
31. Circulating Serum MiRNA-8074 as a Novel Prognostic Biomarker for Multiple Myeloma.
Szudy-Szczyrek A; Mlak R; Mielnik M; Mazurek M; Chocholska S; Podgajna M; Szczyrek M; Homa-Mlak I; Małecka-Massalska T; Hus M
Cells; 2022 Feb; 11(4):. PubMed ID: 35203396
[TBL] [Abstract][Full Text] [Related]
32. [Expression of serum GDF15 and its clinical significance in multiple myeloma patients].
Zhao N; Yang J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 Mar; 39(3):270-5. PubMed ID: 24748192
[TBL] [Abstract][Full Text] [Related]
33. [Contribution to the evaluation of the relationship between angiogenic cytokines, selected biological parameters and prognostic factors in multiple myeloma].
Scudla V; Pika T; Budíková M; Ordeltová M; Minarík J; Zemanová M; Bacovský J; Srovnalík K;
Cas Lek Cesk; 2006; 145(12):929-35. PubMed ID: 17323615
[TBL] [Abstract][Full Text] [Related]
34. miRNAs and Multiple Myeloma: Focus on the Pathogenesis, Prognosis, and Drug Resistance.
Tavakoli Pirzaman A; Ebrahimi P; Hasanpour AH; Shakeri M; Babajani B; Pourali Ganji Z; Babaei H; Rahmati A; Hosseinzadeh R; Doostmohamadian S; Kazemi S
Technol Cancer Res Treat; 2023; 22():15330338231202391. PubMed ID: 37728167
[TBL] [Abstract][Full Text] [Related]
35. Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer.
Chen X; Xu Y; Liao X; Liao R; Zhang L; Niu K; Li T; Li D; Chen Z; Duan Y; Sun J
Tumour Biol; 2016 Sep; 37(9):11927-11936. PubMed ID: 27075472
[TBL] [Abstract][Full Text] [Related]
36. Role of microRNAs in Diagnosis, Prognosis and Management of Multiple Myeloma.
Soliman AM; Lin TS; Mahakkanukrauh P; Das S
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066062
[TBL] [Abstract][Full Text] [Related]
37. MiR-15a, miR-16-1 and miR-17-92 cluster expression are linked to poor prognosis in multiple myeloma.
Gao X; Zhang R; Qu X; Zhao M; Zhang S; Wu H; Jianyong L; Chen L
Leuk Res; 2012 Dec; 36(12):1505-9. PubMed ID: 22959509
[TBL] [Abstract][Full Text] [Related]
38. Serum calcium is an independent prognostic factor of overall survival in Mexican patients with multiple myeloma.
Maillet D; Montiel-Cervantes L; Padilla-González Y; Sánchez-Cortés E; Xolotl-Castillo M; Vela-Ojed J; Reyes-Maldonado E
Rev Invest Clin; 2012; 64(1):17-24. PubMed ID: 22690525
[TBL] [Abstract][Full Text] [Related]
39. Functional analysis of serum microRNAs miR-21 and miR-106a in renal cell carcinoma.
Tusong H; Maolakuerban N; Guan J; Rexiati M; Wang WG; Azhati B; Nuerrula Y; Wang YJ
Cancer Biomark; 2017; 18(1):79-85. PubMed ID: 27814278
[TBL] [Abstract][Full Text] [Related]
40. Low serum level of miR-485-3p predicts poor survival in patients with glioblastoma.
Wang ZQ; Zhang MY; Deng ML; Weng NQ; Wang HY; Wu SX
PLoS One; 2017; 12(9):e0184969. PubMed ID: 28931080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
